Recently, Yang et al. designed human chimeric anti-TNFR2 IgG2 antibodies and found that they effectively eliminated both cancer cells and T-reg cells while leaving T-eff cells unaffected, suggesting a TME-directed killing specificity [314]. This evidence concerns the gene TNFRSF1B and cancer.